This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication


Intraventricular immunovirotherapy: A translational step forward

Oncotarget | Intraventricular immunovirotherapy; a translational step forward
Putative mechanisms of toxicity. Credit: Oncotarget (2023). DOI: 10.18632/oncotarget.28343

A new research perspective titled "Intraventricular immunovirotherapy; a translational step forward" has been published in Oncotarget.

In this new perspective, researchers from Harvard Medical School, Massachusetts Institute of Technology and University of Alabama at Birmingham discuss oncolytic virotherapy with intratumoral engineered type-1 herpes simplex virus (HSV). Intraventricular therapy (IVT) has been proven safe with promising efficacy in recent for treatment of both pediatric and adult high-grade .

The researchers write, "Oncolytic herpes simplex virus type-1 (oHSV) has shown promise in clinical trials in both pediatric and adult ."

However, this approach excludes patients with tumors in surgically inaccessible and/or eloquent brain regions. Current delivery methods are also unable to access/treat those patients with metastatic disease in the spinal cord and/or leptomeningeal disease.

A recent preclinical study has paved the way for clinical translation of intraventricular administration of oHSV by identifying and mitigating the toxicity associated with this route for therapeutic benefit in murine models of disseminated medulloblastoma. This work may ultimately allow for targeting of intractable disease and provides a feasible option for the repetitive dosing of clinically relevant immunovirotherapy, G207.

"Overall, demonstrating the safety and efficacy of IVT with G207 is a significant step towards expanding the capabilities of oHSV, paving the way for new clinical trials, and increasing the potential of an already promising therapy," the researchers conclude.

More information: Joshua D. Bernstock et al, Intraventricular immunovirotherapy; a translational step forward, Oncotarget (2023). DOI: 10.18632/oncotarget.28343

Journal information: Oncotarget
Provided by Impact Journals
Citation: Intraventricular immunovirotherapy: A translational step forward (2023, January 26) retrieved 29 May 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Safety and efficacy of intraventicular immunovirotherapy with oncolytic HSV-1 for CNS cancers


Feedback to editors